Immune Regulation Raises £40.6M in Series B Equity Financing

Immune Regulation, a US and UK based clinical stage biotechnology company, has closed a £40.6 million Series B funding round led by Morningside Ventures. The investment will be used to accelerate the development of drug product candidates that reset the immune system, potentially achieving long term disease remission in autoimmune and allergic diseases. Immune Regulation's first-in-class immune resetting therapies have demonstrated unique efficacy and safety in pre-clinical and human studies without suppressing the immune system.

Immune Regulation Secures £40.6 Million Series B Funding to Advance Immune Resetting Therapies

Immune Regulation is a US and UK based clinical stage biotechnology company pioneering new technologies for regulating and resetting the immune system and developing novel first-in-class therapies for inflammatory and immunological diseases. Its first-in-class immune resetting therapies, IRL201805 (‘1805) and IRL201104 (‘1104), have demonstrated unique efficacy and safety in pre-clinical and human studies without suppressing the immune system. These therapies exhibit short pharmacokinetic activity but reset the immune system from a pro-inflammatory to a regulatory state to induce disease remission in patients with allergic and immune mediated diseases, without the negative effects of chronic current therapies.

A clinical-stage biotechnology company developing novel first-in-class therapies for inflammatory and immunological diseases.

5 years ago

Immune Regulation Secures £40.6 Million Series B Funding to Advance Immune Resetting Therapies

ProblemHealthcare

Solution

Covered on